Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Zoraxel for treatment of ED: Rexahn Pharmaceuticals submits Phase IIb protocol to FDA

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the FDA for ZoraxelTM for the treatment of erectile dysfunction (ED).

4 Mar 2010

Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB

Antares Pharma, Inc. announced today that it has completed enrollment in the double-blind portion of the Company’s Phase 3 clinical trial of Anturol™, its transdermal oxybutynin ATD™ gel for the treatment of overactive bladder (OAB). Top line data from this pivotal trial, which is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA), is expected in the third quarter of this year.

2 Mar 2010

BioSante Pharmaceuticals announces receipt of two US patents directed to 2A/Furin technology

BioSante Pharmaceuticals, Inc. today announced the receipt of two US patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,632,059, covers methods for manufacturing recombinant antibodies.

2 Mar 2010

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

BioSante Pharmaceuticals, Inc., today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications.

22 Feb 2010

Patient registry formed to track clinical course of hypoactive sexual desire disorder

New findings from a European study show that women with low sexual desire and associated distress experience personal and emotional distress related to the sexual issue.

19 Feb 2010

BioSante Pharmaceuticals' LibiGel clinical update to be presented at 2010 ISSWSH annual meeting

BioSante Pharmaceuticals, Inc., will present a LibiGel clinical update at the 2010 Annual Meeting of the International Society for the Study of Women’s Sexual Health (ISSWSH), being held from February 18-20, 2010 in St. Petersburg, Florida.

19 Feb 2010

Trimel BioPharma Holdings updates business developments

Trimel BioPharma Holdings Inc. is today providing an update on a number of operational items that have contributed significantly to advancing the Company and achieving its initial objectives.

10 Feb 2010

Palatin Technologies completes first cohort dosing in bremelanotide trial for sexual dysfunction

Palatin Technologies, Inc. today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. The study will also evaluate consistency of plasma exposure of bremelanotide given as repeated subcutaneous injections.

10 Feb 2010

Long-chain omega-3 polyunsaturated fatty acids may reduce risk of psychotic disorders

Individuals at extremely high risk of developing psychosis appear less likely to develop psychotic disorders following a 12-week course of fish oil capsules containing long-chain omega-3 polyunsaturated fatty acids, according to a report in the February issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

2 Feb 2010

European Patent Office grants a patent for Rexahn Pharmaceuticals' RX-3117

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted a patent for its novel anti-cancer compound, RX-3117.

20 Jan 2010

Positive top-line results from Protox Therapeutics' Phase 2b study of PRX302 announced

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.

11 Jan 2010

NexMed updates corporate activities

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today provided an update on ongoing corporate activities and the status of the Company’s NASDAQ listing.

9 Jan 2010

Author evaluates potential benefits of IAD for treating prostate cancer

'Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature' is the title of an article by P-A. Abrahamsson in the January issue of European Urology, the official journal of the European Association of Urology. The author evaluates available evidence regarding the efficacy and tolerability of intermittent androgen deprivation (IAD) and assess its value in the treatment of prostate cancer (PCa).

5 Jan 2010

FREEDRUGCARD.US launches new Rx savings program to reduce prescription drug prices

If you are looking for the best way to save money on your prescription drugs then FREEDRUGCARD.US is your best option. The free prescription assistance drug card program is sponsored by a non-profit organization and was launched to help all Americans lower the cost of prescription drugs.

31 Dec 2009

Interdisciplinary approach essential for treating men’s' sexual dysfunction

Modern, couple-oriented treatment for male sexual dysfunction takes the psychosocial aspects of sex into account, as well as focussing on the purely physical aspects of the problem.

24 Dec 2009

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Intra-Cellular Therapies, Inc. (ITI) announced at a recent conference on neuropsychiatric diseases the results from a recently completed Phase I clinical study demonstrating ITI-007, the Company's lead antipsychotic drug, interacts with important targets in the living human brain. These key targets are critical to drug action in many neuropsychiatric and related disorders.

21 Dec 2009

Rexahn Pharmaceuticals and TheraTarget sign joint research collaboration agreement

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, and TheraTarget, Inc., a developer of innovative polymer therapeutics for the treatment of cancer, today announced the formation of a joint research collaboration agreement.

15 Dec 2009

New approach to identify molecules that prevent immune cells from attacking body

A study led by a Scripps Research Institute scientist describes a new, highly pragmatic approach to the identification of molecules that prevent a specific type of immune cells from attacking their host. The findings add a powerful new tool to the ongoing search for potential treatments for autoimmune diseases, such as multiple sclerosis (MS), as well as blood cancers, such as myeloid leukemia.

2 Dec 2009

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Ligand Pharmaceuticals Incorporated today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of male hypogonadism and postmenopausal osteoporosis.

20 Nov 2009

Data from second positive pivotal study of PSD502 for treatment of PE presented

At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora")., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).

20 Nov 2009

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Zoraxel for treatment of ED: Rexahn Pharmaceuticals submits Phase IIb protocol to FDA

Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB

BioSante Pharmaceuticals announces receipt of two US patents directed to 2A/Furin technology

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

Patient registry formed to track clinical course of hypoactive sexual desire disorder

BioSante Pharmaceuticals' LibiGel clinical update to be presented at 2010 ISSWSH annual meeting

Trimel BioPharma Holdings updates business developments

Palatin Technologies completes first cohort dosing in bremelanotide trial for sexual dysfunction

Long-chain omega-3 polyunsaturated fatty acids may reduce risk of psychotic disorders

European Patent Office grants a patent for Rexahn Pharmaceuticals' RX-3117

Positive top-line results from Protox Therapeutics' Phase 2b study of PRX302 announced

NexMed updates corporate activities

Author evaluates potential benefits of IAD for treating prostate cancer

FREEDRUGCARD.US launches new Rx savings program to reduce prescription drug prices

Interdisciplinary approach essential for treating men’s' sexual dysfunction

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Rexahn Pharmaceuticals and TheraTarget sign joint research collaboration agreement

New approach to identify molecules that prevent immune cells from attacking body

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Data from second positive pivotal study of PSD502 for treatment of PE presented

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in